Innovative Medicines Initiative (IMI)
macustar is supported by the Innovative Medicines Initiative (IMI) with a financial contribution of 8.025 million Euros, which will be complemented by an in-kind and in-cash contribution of 8.067 million Euros provided by EFPIA partners and ZEISS Meditec AG. The project runs over five years until 31st September 2022.
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organizations, and medicines regulators. IMI is a partnership between the European Union and the European pharmaceutical industries, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects in cash or ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.
More info on IMI: www.imi.europa.eu
Follow IMI on Twitter: @IMI_JU